In partnership with Emory University School of Medicine, Children's Pediatric Nephrology Division is dedicated to finding answers that can make a difference in the lives of children with kidney disease. Our researchers participate in clinical, translational and basic science research, giving children with kidney disease better treatment options and access to innovative therapies.
We are involved in:
- Chronic Kidney Disease in Children (CKiD): A study of the effects of chronic kidney disease on children, sponsored by the National Institutes of Health (NIH).
- Nephrotic Syndrome Study Network (NEPTUNE): A study of children with nephrotic syndrome, a group of symptoms that indicate kidney damage and result in the release of too much protein from the body into the urine. Researchers are seeking to understand the cause and find better treatments.
- Cure Glomerulonephropathy (CureGN): A study of children with minimal change disease, FSGS, IgA nephropathy, Henoch-Schoenlein purpura and membranous nephropathy.
Other areas our researchers are investigating include:
- Testing of an app our team developed to help families better manage nephrotic syndrome
- Adolescent transplant patients’ adherence to their medication and lifestyle regimen, and transitioning them from pediatric- to adult-centered care
- Muscle weakness in cystinosis, an inherited disease that causes cystine to accumulate in cells and form crystals that often leads to kidney failure in childhood, but can also damage other organs
- The impact of chronic kidney disease on the heart and immune system
- Strategies to improve outcome in kidney transplant recipients
- New medications to prevent transplant rejection
- Noninvasive strategies to monitor kidney transplant recipients
Researchers at Children's are currently testing new treatments for Alport syndrome, lupus, C3 glomerulopathy, atypical HUS and nephrotic syndrome. Our team led a multicenter clinical trial of a new approach to treating nephrotic syndrome. The trial was a success and the results were published in December 2018. Researchers are currently leading multicenter clinical trials of a new treatment for distal renal tubular acidosis and a new medicine for controlling high phosphate levels in children with chronic kidney disease.